<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="207">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02318277</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 24360-203</org_study_id>
    <nct_id>NCT02318277</nct_id>
  </id_info>
  <brief_title>A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the safety, tolerability, pharmacokinetics,
      immunogenicity and preliminary efficacy of INCB024360 administered in combination with
      MEDI4736 in subjects with selected advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Phase 1: Incidence of Dose Limiting Toxicities and frequency, duration, and severity of Adverse Events (AEs)</measure>
    <time_frame>Duration of study treatment and up to 90 days after the last dose [approximately 9 months]</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Objective Response Rate (ORR) as determined by radiographic disease assessments per modified Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</measure>
    <time_frame>Measured every 8 weeks for duration of study treatment [approximately 6 months]</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Objective Response Rate (ORR) as determined by radiographic disease assessments per modified RECIST v1.1</measure>
    <time_frame>Measured every 8 weeks for duration of study treatment [approximately 6 months]</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Frequency, duration, and severity of AEs</measure>
    <time_frame>Continuously for duration of study treatment and up to 90 days after the last dose</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Durability of response as measured by the time from the earliest date of disease response until earliest date of disease progression</measure>
    <time_frame>Measured every 8 weeks for duration of active study treatment [approximately 6 months]</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Progression-free survival as measured by the duration from the date of enrollment until the earliest date of disease progression or death</measure>
    <time_frame>Measured every 8 weeks for duration of active study treatment [approximately 6 months]</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Pharmacokinetics (PK) of INCB024360 and MEDI4736 as measured by peak concentration</measure>
    <time_frame>Measured at defined study visits from Cycle 1 Day 1 through 90 days after the last dose of MEDI4736 [approximately 9 months]</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Pharmacokinetics (PK) of INCB024360 and MEDI4736 as measured by time to maximal observed concentration</measure>
    <time_frame>Measured at defined study visits from Cycle 1 Day 1 through 90 days after the last dose of MEDI4736 [approximately 9 months]</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Pharmacokinetics (PK) of INCB024360 and MEDI4736 as area under the concentration-time curve</measure>
    <time_frame>Measured at defined study visits from Cycle 1 Day 1 through 90 days after the last dose of MEDI4736 [approximately 9 months]</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Immunogenicity of MEDI4736 as measured by the number and percentage of subjects who develop detectable anti-drug antibodies (ADAs)</measure>
    <time_frame>Measured at defined study visits from Cycle 1 Day 1 through 90 days after the last dose of MEDI4736 [approximately 9 months]</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Selected Advanced Solid Tumors</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Gastroesophageal Cancer</condition>
  <condition>Urothelial Cancer</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>MEDI4736 + INCB024360</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI4736 at selected dose levels every 2 weeks + INCB024360 25 mg BID as starting dose, followed by dose escalations until MTD or PAD is identified</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI4736</intervention_name>
    <description>MEDI4736 administered intravenously (IV) every two weeks (q2w)</description>
    <arm_group_label>MEDI4736 + INCB024360</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCB024360</intervention_name>
    <description>INCB024360: Oral daily dosing</description>
    <arm_group_label>MEDI4736 + INCB024360</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects, age 18 years or older

          -  Histologically or cytologically confirmed diagnosis of selected locally advanced or
             metastatic solid tumors

          -  Must have failed at least 1 prior treatment regimen for locally advanced or
             metastatic disease or be intolerant to treatment or refuse standard treatment

        Exclusion Criteria:

          -  Laboratory and medical history parameters not within protocol-defined range

          -  Participation in any other study in which receipt of an investigational study drug
             occurred within 28 days or 5 half-lives (whichever is longer) prior to first dose

          -  Prior treatment with immune checkpoint inhibitors (eg, anti-CTLA-4, anti-PD-1,
             anti-PD-L1, and any other antibody or drug specifically targeting T-cell
             co-stimulation) or an IDO inhibitor (exception is tumor types in which a PD-1 pathway
             targeted agent is approved, e.g. melanoma, non-small cell lung cancer.)

          -  Receipt of any anticancer medication in the 21 days prior to receiving the first dose
             of study medication

          -  Has an active or inactive autoimmune process

          -  Evidence of interstitial lung disease or active, non-infectious pneumonitis

          -  Prior radiotherapy within 2 weeks of initiating treatment; Must have recovered from
             all radiation-related toxicities, not require corticosteroids, and not have had
             radiation pneumonitis

          -  Untreated central nervous system (CNS) metastases or CNS metastases that have
             progressed

          -  Currently pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroomi Tada, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center</last_name>
    <phone>1.855.463.3463</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 26, 2016</lastchanged_date>
  <firstreceived_date>November 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
